SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Wolin Edward M)
 

Search: WFRF:(Wolin Edward M) > Phase III study of ...

  • Wolin, Edward M.Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA. (author)

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

  • Article/chapterEnglish2015

Publisher, publication year, extent ...

  • 2015
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-263543
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-263543URI
  • https://doi.org/10.2147/DDDT.S84177DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing carcinoid symptoms refractory to first-generation somatostatin analogues. Adults with carcinoid tumors of the digestive tract were randomly assigned (1:1) to receive pasireotide LAR (60 mg) or octreotide LAR (40 mg) every 28 days. Primary outcome was symptom control based on frequency of bowel movements and flushing episodes. Objective tumor response was a secondary outcome. Progression-free survival (PFS) was calculated in a post hoc analysis. Adverse events were recorded. At the time of a planned interim analysis, the data monitoring committee recommended halting the study because of a low predictive probability of showing superiority of pasireotide over octreotide for symptom control (n=43 pasireotide LAR, 20.9%; n=45 octreotide LAR, 26.7%; odds ratio, 0.73; 95% confidence interval [CI], 0.27-1.97; P=0.53). Tumor control rate at month 6 was 62.7% with pasireotide and 46.2% with octreotide (odds ratio, 1.96; 95% CI, 0.89-4.32; P=0.09). Median (95% CI) PFS was 11.8 months (11.0 - not reached) with pasireotide versus 6.8 months (5.6 - not reached) with octreotide (hazard ratio, 0.46; 95% CI, 0.20-0.98; P=0.045). The most frequent drug-related adverse events (pasireotide vs octreotide) included hyperglycemia (28.3% vs 5.3%), fatigue (11.3% vs 3.5%), and nausea (9.4% vs 0%). We conclude that, among patients with carcinoid symptoms refractory to available somatostatin analogues, similar proportions of patients receiving pasireotide LAR or octreotide LAR achieved symptom control at month 6. Pasireotide LAR showed a trend toward higher tumor control rate at month 6, although it was statistically not significant, and was associated with a longer PFS than octreotide LAR.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Jarzab, BarbaraMaria Sklodowska Curie Mem Canc Ctr, Dept Nucl Med & Endocrine Oncol, Gliwice, Poland.;Inst Oncol, Gliwice Branch, Gliwice, Poland. (author)
  • Eriksson, BarbroUppsala universitet,Endokrin Onkologi(Swepub:uu)barberik (author)
  • Walter, ThomasHop Edouard Herriot, Dept Med Oncol, Lyon, France. (author)
  • Toumpanakis, ChristosRoyal Free Hosp, Gastroenterol & Neuroendocrine Tumours, London NW3 2QG, England. (author)
  • Morse, Michael A.Duke Univ, Med Ctr, Dept Med Oncol, Durham, NC USA. (author)
  • Tomassetti, PaolaUniv Hosp St Orsola, Dept Med & Surg Sci, Bologna, Italy. (author)
  • Weber, Matthias M.Johannes Gutenberg Univ Mainz, Med Klin & Poliklin, D-55122 Mainz, Germany. (author)
  • Fogelman, David R.Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA. (author)
  • Ramage, JohnNorth Hampshire Hosp, Gastroenterol Unit, Basingstoke, Hants, England. (author)
  • Poon, DonaldRaffles Hosp, Dept Med Oncol, Singapore, Singapore.;Duke NUS Grad Med Sch, Singapore, Singapore. (author)
  • Gadbaw, BrianNovartis Pharmaceut, E Hanover, NJ USA. (author)
  • Li, JiangNovartis Pharmaceut, E Hanover, NJ USA. (author)
  • Pasieka, Janice L.Foothills Prov Gen Hosp, Surg & Oncol Fac Med, Calgary, AB T2N 2T9, Canada. (author)
  • Mahamat, AbakarCHU Nice, Hop Archet, Dept Gastrointestinal Oncol, F-06202 Nice, France. (author)
  • Swahn, FredrikKarolinska Univ Sjukhuset, Dept Clin Sci Intervent & Technol, Stockholm, Sweden. (author)
  • Newell-Price, JohnUniv Sheffield, Sch Med & Biomed Sci, Dept Human Metab, Sheffield, S Yorkshire, England.;Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England. (author)
  • Mansoor, WasatChristie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England. (author)
  • Öberg, KjellUppsala universitet,Endokrin Onkologi(Swepub:uu)kjellob (author)
  • Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA.Maria Sklodowska Curie Mem Canc Ctr, Dept Nucl Med & Endocrine Oncol, Gliwice, Poland.;Inst Oncol, Gliwice Branch, Gliwice, Poland. (creator_code:org_t)

Related titles

  • In:Drug Design, Development and Therapy9, s. 5075-50861177-8881

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view